secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outset Medical, Inc. (OM)
CIK:        0001484612
Form:       8-K
Filed at:   2023-08-02T23:59:59+00:00
Accession:  0000950170-23-037134
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Outset Medical Q2 revenue $36M (+44% YoY); pauses TabloCart shipment pending 510(k) clearance
--------------------------------------------------------------------------------

- Q2 net revenue $36.0M, up 44% YoY; product revenue $29.3M (+49.5%).
- Gross margin improved to 21.4% (22.5% non-GAAP) from 15.1% YoY.
- Net loss $44.0M ($0.90/share) vs $43.8M ($0.92) YoY.
- Paused shipment of TabloCart with Prefiltration pending FDA 510(k) clearance; plans to file later this month.
- Reiterated 2023 revenue guidance $144-150M but expects low end due to pause.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1484612/000095017023037134/0000950170-23-037134-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1484612/000095017023037134/om-20230802.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-037134

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer